Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy
Sonia Iyer,Shuang Zhang,Simge Yucel,Heiko Horn,Sean G Smith,Ferenc Reinhardt,Esmee Hoefsmit,Bimarzhan Assatova,Julia Casado,Marie-Charlotte Meinsohn,M Inmaculada Barrasa,George W Bell,Fernando Pérez-Villatoro,Kaisa Huhtinen,Johanna Hynninen,Jaana Oikkonen,Pamoda M Galhenage,Shailja Pathania,Paula T Hammond,Benjamin G Neel,Anniina Farkkila,David Pépin,Robert A Weinberg,Sean G. Smith,M. Inmaculada Barrasa,George W. Bell,Pamoda M. Galhenage,Paula T. Hammond,Benjamin G. Neel,Robert A. Weinberg
DOI: https://doi.org/10.1158/2159-8290.cd-20-0818
IF: 28.2
2020-11-06
Cancer Discovery
Abstract:Despite advances in immuno-oncology, the relationship between tumor genotypes and response to immunotherapy remains poorly understood, particularly in high-grade serous tubo-ovarian carcinomas (HGSC). We developed a series of mouse models that carry genotypes of human HGSCs and grow in syngeneic immunocompetent hosts to address this gap. We transformed murine-fallopian tube epithelial cells to phenocopy homologous recombination-deficient tumors through a combined loss of <i>Trp53, Brca1, Pten, and Nf1</i> and overexpression of <i>Myc</i> and <i>Trp53</i> <sup>R172H</sup>, which was contrasted with an identical model carrying wild-type <i>Brca1</i>. For homologous recombination-proficient tumors, we constructed genotypes combining loss of <i>Trp53</i> and overexpression of <i>Ccne1, Akt2, and Trp53</i> <sup>R172H</sup>, and driven by <i>KRAS</i> <sup>G12V</sup> or <i>Brd4</i> or <i>Smarca4</i> overexpression. These lines form tumors recapitulating human disease, including genotype-driven responses to treatment, and enabled us to identify follistatin as a driver of resistance to checkpoint inhibitors. These data provide proof of concept that our models can identify new immunotherapy targets in HGSC. SIGNIFICANCE: We engineered a panel of murine fallopian tube epithelial cells bearing mutations typical of HGSC and capable of forming tumors in syngeneic immunocompetent hosts. These models recapitulate tumor microenvironments and drug responses characteristic of human disease. In a <i>Ccne1</i>-overexpressing model, immune-checkpoint resistance was driven by follistatin.<i>This article is highlighted in the In This Issue feature, p. 211</i>.
oncology